Abstract
Objectives Develop an interpretable AI algorithm to rule out normal large bowel endoscopic biopsies saving pathologist resources.
Design Retrospective study.
Setting One UK NHS site was used for model training and internal validation. External validation conducted on data from two other NHS sites and one site in Portugal.
Participants 6,591 whole-slides images of endoscopic large bowel biopsies from 3,291 patients (54% Female, 46% Male).
Main outcome measures Area under the receiver operating characteristic and precision recall curves (AUC-ROC and AUC-PR), measuring agreement between consensus pathologist diagnosis and AI generated classification of normal versus abnormal biopsies.
Results A graph neural network was developed incorporating pathologist domain knowledge to classify the biopsies as normal or abnormal using clinically driven interpretable features. Model training and internal validation were performed on 5,054 whole slide images of 2,080 patients from a single NHS site resulting in an AUC-ROC of 0.98 (SD=0.004) and AUC-PR of 0.98 (SD=0.003). The predictive performance of the model was consistent in testing over 1,537 whole slide images of 1,211 patients from three independent external datasets with mean AUC-ROC = 0.97 (SD=0.007) and AUC-PR = 0.97 (SD=0.005). Our analysis shows that at a high sensitivity threshold of 99%, the proposed model can, on average, reduce the number of normal slides to be reviewed by a pathologist by 55%. A key advantage of IGUANA is its ability to provide an explainable output highlighting potential abnormalities in a whole slide image as a heatmap overlay in addition to numerical values associating model prediction with various histological features. Example results with can be viewed online at https://iguana.dcs.warwick.ac.uk/.
Conclusions An interpretable AI model was developed to screen abnormal cases for review by pathologists. The model achieved consistently high predictive accuracy on independent cohorts showing its potential in optimising increasingly scarce pathologist resources and for achieving faster time to diagnosis. Explainable predictions of IGUANA can guide pathologists in their diagnostic decision making and help boost their confidence in the algorithm, paving the way for future clinical adoption.
What is already known on this topic
Increasing screening rates for early detection of colon cancer are placing significant pressure on already understaffed and overloaded histopathology resources worldwide and especially in the United Kingdom1.
Approximately a third of endoscopic colon biopsies are reported as normal and therefore require minimal intervention, yet the biopsy results can take up to 2-3 weeks2.
AI models hold great promise for reducing the burden of diagnostics for cancer screening but require incorporation of pathologist domain knowledge and explainability.
What this study adds
This study presents the first AI algorithm for rule out of normal from abnormal large bowel endoscopic biopsies with high accuracy across different patient populations.
For colon biopsies predicted as abnormal, the model can highlight diagnostically important biopsy regions and provide a list of clinically meaningful features of those regions such as glandular architecture, inflammatory cell density and spatial relationships between inflammatory cells, glandular structures and the epithelium.
The proposed tool can both screen out normal biopsies and act as a decision support tool for abnormal biopsies, therefore offering a significant reduction in the pathologist workload and faster turnaround times.
Competing Interest Statement
SG, DS and NR are co-founders of Histofy Ltd. DS reports personal fees from Royal Philips, outside the submitted work. NR and FM report research funding from GlaxoSmithKline. All other authors declare no competing interests.
Funding Statement
All authors would like to acknowledge the support from the PathLAKE digital pathology consortium which is funded by the Data to Early Diagnosis and Precision Medicine strand of the government Industrial Strategy Challenge Fund managed and delivered by UK Research and Innovation (UKRI). FM acknowledges funding from EPSRC grant EP/W02909X/1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted under Health Research Authority National Research Ethics approval 15/NW/0843; IRAS 189095 and the Pathology image data Lake for Analytics, Knowledge and Education (PathLAKE) research ethics committee approval (REC reference 19/SC/0363, IRAS project ID 257932, South Central - Oxford C Research Ethics Committee).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.